AR056062A1 - Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion - Google Patents
Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacionInfo
- Publication number
- AR056062A1 AR056062A1 ARP060102333A ARP060102333A AR056062A1 AR 056062 A1 AR056062 A1 AR 056062A1 AR P060102333 A ARP060102333 A AR P060102333A AR P060102333 A ARP060102333 A AR P060102333A AR 056062 A1 AR056062 A1 AR 056062A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- sodium alginate
- components
- proton pump
- total
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000428 dust Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 18
- 239000003159 antacid agent Substances 0.000 abstract 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 7
- 235000010413 sodium alginate Nutrition 0.000 abstract 7
- 229940005550 sodium alginate Drugs 0.000 abstract 7
- 239000000661 sodium alginate Substances 0.000 abstract 7
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 5
- 239000000612 proton pump inhibitor Substances 0.000 abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 5
- 229940069428 antacid Drugs 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 2
- 229940072056 alginate Drugs 0.000 abstract 2
- 235000010443 alginic acid Nutrition 0.000 abstract 2
- 229920000615 alginic acid Polymers 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 239000003186 pharmaceutical solution Substances 0.000 abstract 1
- 239000007971 pharmaceutical suspension Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion farmacéutica antiácida en forma de polvo para la neutralizacion rápida y prolongada de la acidez gástrica con actividad protectora de las mucosas, destinada a preparar por dispersion en agua una solucion o suspension farmacéutica de uso oral, en donde la composicion comprende: alginato de sodio, un agente antiácido soluble o una combinacion de antiácidos, un inhibidor de la bomba protonica, y agentes diluyentes y edulcorantes; en donde: a) por lo menos un 30% del alginato de sodio presente en la formulacion junto con el total del inhibidor de la bomba protonica se encuentran distribuidos homogéneamente sobre la superficie del total del agente antiácido soluble o de la combinacion de antiácidos de la composicion; y b) el resto, aproximadamente un 70%, del alginato de sodio presente en la formulacion contiene un porcentaje de humedad inferior al 2%. Un proceso de elaboracion que comprende: a) mezclar la totalidad del agente antiácido soluble o combinacion de antiácidos de la composicion, el total del inhibidor de la bomba protonica y hasta el 30% del alginato de sodio de la composicion son mezclados hasta homogeneidad de la mezcla a temperatura ambiente en una granuladora conveniente; b) impregnar la mezcla de tales componentes con agua en la misma granuladora incorporando un peso total de agua no superior al 10% del peso total de la composicion farmacéutica total; c) secar la mezcla así obtenida a presion normal, bajo vacío o lecho fluido a una temperatura inferior a 50sC hasta humedad residual inferior al 2%; d) incorporar al granulado obtenido en la etapa anterior c), el resto del alginato de sodio de la composicion y componentes de la formula también tamizados y con humedad inferior al 2% y mezclar durante 30 minutos; e) controlar que la humedad residual de la composicion sea inferior al 2%, preferentemente inferior al 0,7%, y finalmente dosificar y envasar. De esta forma la granulacion humeda del inhibidor de la bomba protonica con la totalidad del agente o agentes antiácidos de la composicion, otros componentes y hasta el 30% del alginato de la composicion permite lograr una mayor estabilidad del inhibidor de la bomba protonica a través de la distribucion homogénea de dicho inhibidor y parte del alginato de la composicion sobre la superficie del agente antiácido. La mezcla a posteriori con hasta el 70% del alginato de sodio presente en la formulacion y otros componentes de la misma favorecería la rápida dispersion del resto del alginato de sodio de la composicion e incrementaría rápidamente la viscosidad de la solucion o suspension al mezclar la composicion con agua previa a la ingesta logrando una rápida formacion de una suspension homogénea de todos los componentes de la composicion a posterior de su reconstruccion con agua u otra bebida. Preferiblemente, dicha reconstitucion se realiza en un tiempo inferior a 2 minutos.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP060102333A AR056062A1 (es) | 2006-06-05 | 2006-06-05 | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
| UY30382A UY30382A1 (es) | 2006-06-05 | 2007-05-31 | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
| DE07380159T DE07380159T1 (de) | 2006-06-05 | 2007-06-01 | Pharmazeutische Säureschutzzusammensetzung in Pulverform, pharmazeutische Zubereitung damit und Herstellungsverfahren dafür |
| PL07380159T PL1905426T3 (pl) | 2006-06-05 | 2007-06-01 | Kompozycja farmaceutyczna przeciw-kwasowa w postaci proszku, preparat farmaceutyczny zawierający ją, oraz sposób jej wytwarzania |
| ES07380159T ES2301455T3 (es) | 2006-06-05 | 2007-06-01 | Composición farmacéutica antiácida en forma de polvo, preparación farmacéutica que la contiene y proceso para su preparación |
| EP07380159A EP1905426B1 (en) | 2006-06-05 | 2007-06-01 | Anti-acid pharmaceutical composition in powder form; pharmaceutical preparation containing it and process for making it |
| BRPI0704028A BRPI0704028B8 (pt) | 2006-06-05 | 2007-06-04 | Composição farmacêutica antiácida em forma de pó para a neutralização rápida e prolongada da acidez gástrica, preparação farmacêutica em forma de pó e procedimento para preparar a composição |
| UAA200706189A UA95224C2 (ru) | 2006-06-05 | 2007-06-04 | Антацидная фармацевтическая композиция в порошковой форме, фармацевтическое средство, ее содержащее, и способ ее получения |
| RU2007120753/15A RU2351332C2 (ru) | 2006-06-05 | 2007-06-04 | Порошкообразная антацидная фармацевтическая композиция, содержащий ее фармацевтический препарат и способ ее получения |
| MX2007006722A MX2007006722A (es) | 2006-06-05 | 2007-06-05 | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion. |
| US11/810,453 US7968118B2 (en) | 2006-06-05 | 2007-06-05 | Anti-acid pharmaceutical composition in powder form and process for making it |
| US12/643,095 US8093271B2 (en) | 2006-06-05 | 2009-12-21 | Anti-acid pharmaceutical composition in powder form and process for making it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP060102333A AR056062A1 (es) | 2006-06-05 | 2006-06-05 | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056062A1 true AR056062A1 (es) | 2007-09-19 |
Family
ID=38572778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102333A AR056062A1 (es) | 2006-06-05 | 2006-06-05 | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7968118B2 (es) |
| EP (1) | EP1905426B1 (es) |
| AR (1) | AR056062A1 (es) |
| BR (1) | BRPI0704028B8 (es) |
| DE (1) | DE07380159T1 (es) |
| ES (1) | ES2301455T3 (es) |
| MX (1) | MX2007006722A (es) |
| PL (1) | PL1905426T3 (es) |
| RU (1) | RU2351332C2 (es) |
| UA (1) | UA95224C2 (es) |
| UY (1) | UY30382A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008019339A1 (de) * | 2008-04-16 | 2009-10-22 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Zusammensetzung für die medizinische Anwendung, insbesondere Antazidum |
| AU2011242177B8 (en) * | 2010-04-23 | 2015-06-04 | S-Biotek Holding Aps | A solid pharmaceutical composition for neutralizing stomach acid |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TR201723199A2 (tr) * | 2017-12-30 | 2019-07-22 | Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi | Yeni farmasötik bileşimler. |
| TW202126301A (zh) | 2019-10-04 | 2021-07-16 | 愛爾蘭商席歐拉斯製藥有限公司 | 小兒懸浮調配物 |
| FR3107183B1 (fr) * | 2020-02-19 | 2022-04-29 | Amsellem Jean Paul | Composition pour le traitement des vertiges |
| CN114288243B (zh) * | 2022-01-24 | 2023-02-07 | 中国药科大学 | 一种口服抗酸原位凝胶及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4744986A (en) * | 1986-03-07 | 1988-05-17 | Rorer Pharmaceutical Corporation | Process for the preparation of a viscosity-stable antacid composition |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| AU7218294A (en) * | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-alginate combinations |
| SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| WO1998023272A1 (en) * | 1996-11-27 | 1998-06-04 | The Procter & Gamble Company | Compositions and methods for the treatment of gastrointestinal disorders |
| BR0300882A (pt) * | 2003-04-09 | 2005-05-10 | Cmax Otimizacao De Resultados | Composições farmacêuticas, método e uso de formulação para tratamento e prevenção de infecções associadas com helicobacter pylori em mamìferos e no ser humano |
| MXPA06000524A (es) * | 2003-07-18 | 2006-08-11 | Santarus Inc | Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido. |
| WO2005032554A1 (en) * | 2003-10-03 | 2005-04-14 | Astron Research Pvt. Ltd | A novel transmucosal delivery system |
-
2006
- 2006-06-05 AR ARP060102333A patent/AR056062A1/es not_active Application Discontinuation
-
2007
- 2007-05-31 UY UY30382A patent/UY30382A1/es active IP Right Grant
- 2007-06-01 PL PL07380159T patent/PL1905426T3/pl unknown
- 2007-06-01 DE DE07380159T patent/DE07380159T1/de active Pending
- 2007-06-01 EP EP07380159A patent/EP1905426B1/en active Active
- 2007-06-01 ES ES07380159T patent/ES2301455T3/es active Active
- 2007-06-04 BR BRPI0704028A patent/BRPI0704028B8/pt active IP Right Grant
- 2007-06-04 UA UAA200706189A patent/UA95224C2/ru unknown
- 2007-06-04 RU RU2007120753/15A patent/RU2351332C2/ru active
- 2007-06-05 US US11/810,453 patent/US7968118B2/en not_active Expired - Fee Related
- 2007-06-05 MX MX2007006722A patent/MX2007006722A/es active IP Right Grant
-
2009
- 2009-12-21 US US12/643,095 patent/US8093271B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UY30382A1 (es) | 2007-07-31 |
| BRPI0704028B8 (pt) | 2022-05-10 |
| BRPI0704028A (pt) | 2008-04-01 |
| MX2007006722A (es) | 2009-02-18 |
| PL1905426T3 (pl) | 2013-02-28 |
| US7968118B2 (en) | 2011-06-28 |
| EP1905426B1 (en) | 2012-09-05 |
| RU2351332C2 (ru) | 2009-04-10 |
| ES2301455T3 (es) | 2013-01-23 |
| DE07380159T1 (de) | 2008-08-21 |
| EP1905426A2 (en) | 2008-04-02 |
| EP1905426A3 (en) | 2008-05-21 |
| BRPI0704028B1 (pt) | 2021-02-09 |
| UA95224C2 (ru) | 2011-07-25 |
| ES2301455T1 (es) | 2008-07-01 |
| RU2007120753A (ru) | 2008-12-10 |
| US20070281015A1 (en) | 2007-12-06 |
| US20100160382A1 (en) | 2010-06-24 |
| US8093271B2 (en) | 2012-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0704028B8 (pt) | Composição farmacêutica antiácida em forma de pó para a neutralização rápida e prolongada da acidez gástrica, preparação farmacêutica em forma de pó e procedimento para preparar a composição | |
| KR100507400B1 (ko) | 안정한 경구용 의약 조성물 | |
| ES2875966T3 (es) | Preparación de formas farmacéuticas estables | |
| CN101843567B (zh) | 化妆品贴膜用凝胶片 | |
| RU2693491C2 (ru) | Способ получения фармацевтической системы доставки | |
| CN115916392A (zh) | 在用于生产负载型微胶囊的方法中的经表面反应碳酸钙 | |
| CA1072413A (en) | Poloxamer gel systems with gelling temperatures higher than room temperature | |
| ES2593584T3 (es) | Sellante de fibrina en polvo seco | |
| CA2609766A1 (en) | Product for the management of inflammations, pressure sores and/or oral sores (aphthas) as well as the use of such product | |
| EP2139451B1 (en) | Topical compositions containing magaldrate | |
| CA2807266A1 (en) | Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair | |
| KR100976071B1 (ko) | 조성물 내에서의 또는 조성물에 관련된 개선책 | |
| CN1988876A (zh) | 牙膏组合物 | |
| ES2302691T3 (es) | Formulaciones antihelminticas. | |
| Hegge et al. | Evaluation of novel alginate foams as drug delivery systems in antimicrobial photodynamic therapy (aPDT) of infected wounds—an in vitro study: studies on curcumin and curcuminoides XL | |
| US20150351362A1 (en) | Animal toilet sand | |
| Nakhat et al. | Studies on buccoadhesive tablets of terbutaline sulphate. | |
| AR045719A1 (es) | Formulacion farmaceutica que comprende levotiroxina sodica, celulosa microcristalina y almidon pregelatinizado; uso de la misma para la fabricacion de un medicamento y proceso para preparar dicha formulacion | |
| JP5516401B2 (ja) | 固形内服製剤 | |
| RU2562993C1 (ru) | Гелевый состав слезоточивого раздражающего действия для средств самообороны (варианты) | |
| EA006582B1 (ru) | Фармацевтический дезинфицирующий препарат на основе уснината натрия и лекарственных растений, (его варианты) и способы их изготовления | |
| JPS58105914A (ja) | 持続性活性制酸剤 | |
| JP4965096B2 (ja) | 圧縮成型製剤 | |
| CN103961367A (zh) | 一种洗液泡腾片及其制备方法 | |
| ES2606947T3 (es) | Composición para combatir epistaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FC | Refusal |